#United States #medical technology #Middletown #RevMedica #Surgical Stapling

RevMedica's New Leadership

RevMedica, a pioneering medical technology firm recognized for its advanced surgical stapling solutions, has announced the appointment of Mike Jones as its new Chief Executive Officer and board member. This strategic move comes as the company aims to enhance its clinical development and commercialization efforts further.

Mike Jones, with over three decades of global MedTech experience, is best known for his role as Senior Vice President and President of the Endoscopy division at Boston Scientific, a division that commands a significant $3 billion in revenue. His extensive background covering research and development, commercial execution, and strategic business development at Boston Scientific positions him perfectly to lead RevMedica through its next growth phase.

Taking the helm from Tom Wenchell, RevMedica's founder, Jones will focus on refining the company's strategic direction while they prepare for regulatory approvals and market entry. Wenchell is transitioning to the role of President and Chief Operating Officer, where he will continue to drive product development and day-to-day operations.

"RevMedica signifies an exciting opportunity to introduce vital innovations in a critical surgical area," Jones emphasized. He elaborated on the company's differentiated technology platform, which promises to enhance the way surgeons assess and manage tissue during surgical procedures.

At the heart of RevMedica's product offerings is a powered surgical stapling platform that integrates real-time tissue sensing and feedback. This technology is designed to assist surgeons in making more informed decisions during critical intraoperative moments by providing actionable insights into tissue characteristics.

Tom Wenchell, while commending Jones’ commercial leadership skills and strategic vision, expressed enthusiasm for the opportunity to collaborate closely and leverage their combined expertise to enhance RevMedica's capabilities. Such a leadership structure is expected to balance RevMedica's technical prowess with proven market experience, preparing the company for a robust market presence.

With over 30 US patents issued, the company is poised for a significant market introduction in the near future. The FDA has designated RevMedica’s surgical technology as a Safer Technologies product in October 2024, highlighting its commitment to developing innovative solutions for soft-tissue surgery.

In a rapidly evolving medical landscape, Jones' leadership is anticipated to bring additional focus and energy to RevMedica's innovative undertakings. The future appears promising for RevMedica as it sets out to solidify its position in the surgical technology sector.

As the company heads into this exciting chapter, interested healthcare professionals can stay updated on their progress and groundbreaking advancements by visiting their website at revmedica.com.

RevMedica remains committed to delivering meaningful innovations that enhance surgical outcomes, focusing on safety and efficiency in medical practices. Stay tuned for more reports on RevMedica’s journey and the potential impact of their intelligent surgical stapling solutions on the healthcare industry.